Skip to main content
Fr Donate
  1. Home
  2. Get involved
  3. Advocacy
  4. What we are doing
  5. Drug access
  6. Feedback on cancer drugs

Feedback on cancer drugs from people affected by cancer and clinicians

  1. Home
  2. Get involved
  3. Advocacy
  4. What we are doing
  5. Drug access
  6. Feedback on cancer drugs

The Canadian Cancer Society is dedicated to improving the lives of people with cancer. We collect feedback about cancer drugs from people with cancer, their caregivers, and clinicians as part of this effort. This feedback helps shape recommendations for which drugs are covered under provincial and territorial drug plans.   

We share your feedback with two organizations. The Canadian Agency for Drugs and Technologies in Health (CADTH) is an independent, not-for-profit organization. It provides evidence and recommendations about medical procedures, devices and drugs (among other things) to healthcare decision-makers. The National Institute of Excellence in Health and Social Services (INESSS) promotes best practices and the efficient use of resources for health and social services. To ensure adequate representation across the cancer continuum, we will be focusing primarily on rare cancers and those that do not have representation through another organization. 
A cancer patient being hugged by their caregiver

People with cancer and their caregivers

We want to hear from people living with and beyond cancer, as well as their caregivers. They have first-hand knowledge of life with cancer. Their experience means they can give us valuable feedback about the benefits and drawbacks of current treatments. They can also help assess new treatments.
A cancer patient being hugged by their caregiver

Current Feedback Opportunities 

Metastatic Castration-Resistant Prostate Cancer Survey

Metastatic Castration-Resistant Prostate Cancer Survey: To better inform the Canadian Agency for Drugs and Technologies in Health (CADTH) and l’Institut national d’excellence en sa nté et en services sociaux (INESSS) , the Canadian Cancer Society (CCS) has launched a survey to understand the experience of people impacted by metastatic castrate-resistant prostate cancer. We are also seeking feedback on the advantages and disadvantages of the drugs Lynparza (Olaparib) and Talzenna (Talazoparib) from people who have taken it. You do not have to have tried these drugs to complete this survey. The survey will take about 15-20 minutes to complete, and if you would like to participate, we ask that you complete it by April 27, 2023. 

Advisory Panel

Voicing your needs and concerns is a great way to help us bring your voice to bear on improving the quality of life for many people affected by cancer, which is why the Canadian Cancer Society is inviting you to be part of our advisory panel. We may invite you to participate in surveys, focus groups or other engagement activities. 

Patient and doctor talking in an examination room

Clinicians

The Canadian Cancer Society gathers feedback from clinicians on open calls and draft recommendations posted by CADTH and INESSS. Clinician feedback helps these organizations make recommendations to healthcare decision makers that maximize the use of limited resources and enhance the quality of drug reviews.
Patient and doctor talking in an examination room

Past submissions

To view submissions that have been made to CADTH, including those made by CCS, please visit CADTH’s Reimbursement Review Reports. (Note that it takes time for the submissions to be posted to this site, so you may need to check back to find the results of a specific CCS submission.)

Dostarlimab (Jemperli)
Indication: Dostarlimab is indicated for monotherapy for the treatment of adult patients with recurrent or advanced mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) endometrial cancer (EC) that has progressed on or following prior treatment with a platinum containing regimen.

Selpercatinib (Retevmo) 
Indication: Retevmo is indicated as monotherapy for the treatment of RET-mutant medullary thyroid cancer in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease, RET fusion-positive differentiated thyroid carcinoma in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib.

Leuprolide mesylate (Camcevi)
Indication: Camcevi is indicated for the palliative treatment of advanced prostate cancer. Camcevi 42 mg is indicated for the treatment of hormone-dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.

Cabozantinib (Cabometyx)
Indication: Treatment of adult and adolescent patients 12 years of age and older with differentiated thyroid carcinoma (papillary and follicular together) that has progressed following prior therapy and who are radioactive iodine-resistant or are not eligible for radioactive iodine therapies.

Darolutamide (Nubeqa)
Indication: Darolutamide is indicated for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel.

Abiraterone acetate and prednisolone
Indication: For the treatment of high-risk non-metastatic prostate cancer.

Abiraterone acetate and prednisone/dexamethasone with docetaxel
Indication: For the treatment of metastatic castration-sensitive prostate cancer in combination with androgen deprivation therapy.

Lutetium vipivotide tetraxetan (Pluvicto)
Indication: The treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with anti-androgen drugs and taxane-based chemotherapy or who are not medically suitable for taxane based chemotherapy.